Global Alliance for TB Drug Development

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2000-01-01

Employees: 51

Market Cap: -

Website: http://www.tballiance.org

Clinical Trials

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: PA-824 200mg
Drug: PA-824 50mg

First Posted Date: 2013-04-12

Last Posted Date: 2019-09-06

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 32

Registration Number: NCT01830439

Locations: 🇺🇸
MDS Pharma Services (Celerion), Lincoln, Nebraska, United States

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: PA-824 1000 mg

First Posted Date: 2013-04-11

Last Posted Date: 2016-01-14

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 16

Registration Number: NCT01828827

Locations: 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States

Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Midazolam
Drug: PA-824

First Posted Date: 2013-01-15

Last Posted Date: 2019-09-12

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 14

Registration Number: NCT01768273

Locations: 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: TMC207 (J)
Drug: Rifafour
Drug: PA-824 (PA)
Drug: clofazimine (C)
Drug: pyrazinamide (Z)

First Posted Date: 2012-09-24

Last Posted Date: 2016-12-13

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 105

Registration Number: NCT01691534

Locations: 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦
Task Applied Science, Karl Bremer Hospita, Cape Town, South Africa

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Moxifloxacin (M)
Drug: Rifafour
Drug: Pretomid (Pa)
Drug: Pyrazinamide (Z)

First Posted Date: 2011-12-23

Last Posted Date: 2018-06-28

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 207

Registration Number: NCT01498419

Locations: 🇹🇿
Ifakara Health Institute, Bagamoyo, Tanzania
🇿🇦
The Aurum Institute: Tembisa Hospital, Tembisa, South Africa
🇿🇦
Klerksdorp Tshepong Hospital, Klerksdorp, South Africa

and more 5 locations

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: TMC207
Drug: Pyrazinamide
Drug: PA-824
Drug: Rifafour
Drug: Moxifloxacin

First Posted Date: 2010-10-07

Last Posted Date: 2017-02-28

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 85

Registration Number: NCT01215851

Locations: 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦
Task Applied Science, Karl Bremer Hospital, Cape Town, South Africa

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: TMC207
Drug: Rifafour e-275 mg

First Posted Date: 2010-10-06

Last Posted Date: 2017-04-26

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 68

Registration Number: NCT01215110

Locations: 🇿🇦
Karl Bremer Hospital, Belville, Cape Town, South Africa

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Rifafour e-275 mg
Drug: PA-824

First Posted Date: 2009-07-22

Last Posted Date: 2019-09-20

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 69

Registration Number: NCT00944021

Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis

Phase 3

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin

First Posted Date: 2009-03-18

Last Posted Date: 2017-03-21

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 1931

Registration Number: NCT00864383

Locations: 🇮🇳
Mahatma Gandhi Medical College& Hospital, Jaipur, Rajsthan, India
🇮🇳
A-One Hospital, Delhi, India
🇮🇳
Centre for advanced lung and sleep disorders, New Delhi, India

and more 44 locations

PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: PA-824

First Posted Date: 2007-12-05

Last Posted Date: 2017-05-15

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 69

Registration Number: NCT00567840

Locations: 🇿🇦
Tiervlei Trials Center, Stellenbosch University, Cape Town, Cape Province, South Africa
🇿🇦
University of Cape Town Lung Institute, Cape Town, Cape Province, South Africa

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy